{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:53:16Z","timestamp":1788612796457,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":735,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jcf.2020.04.010","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:44:24Z","timestamp":1591836264000},"page":"746-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment"],"prefix":"10.1016","volume":"19","author":[{"given":"Tara N.","family":"Guhr Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Cholon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Quinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8081-2986","authenticated-orcid":false,"suffix":"Jr","given":"Charles R.","family":"Esther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"44","key":"10.1016\/j.jcf.2020.04.010_bib0001","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"46","key":"10.1016\/j.jcf.2020.04.010_bib0002","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad. Sci. USA"},{"issue":"17","key":"10.1016\/j.jcf.2020.04.010_bib0003","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jcf.2020.04.010_bib0004","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2020.04.010_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2020.04.010_bib0006","doi-asserted-by":"crossref","first-page":"00082","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2020.04.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619844424","article-title":"The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy","volume":"13","author":"Lommatzsch","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jcf.2020.04.010_bib0008","unstructured":"(CHMP) CfMPfHU. Kalydeco: EPAR- Public Assessment Report. 201206\/08\/2012. Contract No.: EMA\/473297\/2012."},{"issue":"246","key":"10.1016\/j.jcf.2020.04.010_bib0009","doi-asserted-by":"crossref","first-page":"ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.jcf.2020.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"21","key":"10.1016\/j.jcf.2020.04.010_bib0011","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2020.04.010_bib0012","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2020.04.010_bib0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-62703-125-7_8","article-title":"Human nasal and tracheo-bronchial respiratory epithelial cell culture","volume":"945","author":"Fulcher","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcf.2020.04.010_bib0014","first-page":"IE.9.1","article-title":"Production of 3-D airway organoids from primary human airway basal cells and their use in high-throughput screening","volume":"1237","author":"Hild","year":"2016","journal-title":"Curr Protoc Stem Cell Biol"},{"issue":"3","key":"10.1016\/j.jcf.2020.04.010_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1165\/rcmb.2005-0286OC","article-title":"SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis","volume":"34","author":"Grubb","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.jcf.2020.04.010_bib0016","doi-asserted-by":"crossref","first-page":"C1578","DOI":"10.1152\/ajpcell.2000.279.5.C1578","article-title":"Expression of nucleotide-regulated Cl(-) currents in CF and normal mouse tracheal epithelial cell lines","volume":"279","author":"Thomas","year":"2000","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"10.1016\/j.jcf.2020.04.010_bib0017","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2020.04.010_bib0018","doi-asserted-by":"crossref","first-page":"L550","DOI":"10.1152\/ajplung.00186.2016","article-title":"Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770","volume":"311","author":"Gentzsch","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"246","key":"10.1016\/j.jcf.2020.04.010_bib0019","doi-asserted-by":"crossref","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci Transl Med"},{"issue":"S1569-1993","key":"10.1016\/j.jcf.2020.04.010_bib0020","first-page":"30035","article-title":"Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy","volume":"20","author":"Guimbellot","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"24","key":"10.1016\/j.jcf.2020.04.010_bib0021","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1093\/hmg\/ddx367","article-title":"Mutation-specific downregulation of CFTR2 variants by gating potentiators","volume":"26","author":"Avramescu","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.jcf.2020.04.010_bib0022","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1242\/dev.140103","article-title":"Lung organoids: current uses and future promise","volume":"144","author":"Barkauskas","year":"2017","journal-title":"Development"},{"key":"10.1016\/j.jcf.2020.04.010_bib0023","first-page":"e27112","article-title":"Novel opportunities for CFTR-targeting drug development using organoids","volume":"1","author":"Dekkers","year":"2013","journal-title":"Rare Dis (Austin, Tex)"},{"key":"10.1016\/j.jcf.2020.04.010_bib0024","unstructured":"National Center for Biotechnology Information. PubChem Database. Ivacaftor, CID=16220172, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/16220172 (accessed on February 14, 2020)"},{"key":"10.1016\/j.jcf.2020.04.010_bib0025","unstructured":"National Center for Biotechnology Information. PubChem Database. Lumacaftor, CID=16678941, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/16678941 (accessed on February 14, 2020)"},{"key":"10.1016\/j.jcf.2020.04.010_bib0026","unstructured":"National Center for Biotechnology Information. PubChem Database. Tezacaftor, CID=46199646, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tezacaftor (accessed on February 14, 2020)"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320301235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320301235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:43:01Z","timestamp":1761601381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320301235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1569199320301235"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.04.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}